Merck announces new phase 2 data on investigational triple combination therapy MK-3682B
Merc announced the first sustained virologic response results 12 weeks after completion of therapy (SVR12, considered virologic cure) from C-SURGE, an ongoing, open label Phase 2 clinical trial evaluating MK-3682B, in treatment-experienced patients with HCV GT. April 22, 2017